10-K: Shattuck Labs Focuses on DR3 Antibody Program, Files 10-K Report

Shattuck Labs' 2024 10-K filing highlights a strategic shift towards its SL-325 DR3 antagonist antibody program for inflammatory bowel disease, alongside financial results and risk factors.

Summary

• Shattuck Labs' 10-K filing for the year ended December 31, 2024, details the company's business, financial condition, and risk factors.
• The company is focusing on developing SL-325, a DR3 antagonist antibody, for inflammatory bowel disease (IBD).
• Shattuck Labs anticipates filing an IND application for SL-325 in Q3 2025 and completing Phase 1 enrollment in Q2 2026.
• The company reported a net loss of $75.4 million for 2024, compared to $87.3 million in 2023.
• As of December 31, 2024, Shattuck Labs had $73.0 million in cash, cash equivalents, and investments, which are expected to fund operations into 2027.
• Shattuck Labs discontinued the clinical development of SL-172154, leading to a restructuring plan and workforce reduction.
• The company is developing multiple preclinical DR3-based bispecific antibodies, with lead candidate nomination expected in 2025.
• Shattuck Labs is also advancing TRIM7 inhibitors through preclinical development for oncology.
• The company terminated its collaboration agreements with Ono Pharmaceutical and ImmunoGen.
• Shattuck Labs relies on third-party manufacturers for its product candidates and faces competition from other companies developing therapies for immune-mediated diseases.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is focusing on a promising drug candidate and has sufficient cash to fund operations in the near term, it also reported a significant net loss and discontinued a clinical development program. The overall sentiment is neutral.

Positives

• Shattuck Labs is focusing on a promising DR3 antagonist antibody program for IBD.
• The company has a clear timeline for IND filing and Phase 1 enrollment for SL-325.
• Shattuck Labs has sufficient cash to fund operations into 2027.
• The company is developing multiple preclinical DR3-based bispecific antibodies.
• Shattuck Labs is also advancing TRIM7 inhibitors through preclinical development for oncology.

Negatives

• Shattuck Labs reported a significant net loss of $75.4 million for 2024.
• The company has no products approved for commercial sale and has never generated revenue from product sales.
• Shattuck Labs discontinued the clinical development of SL-172154.
• The company terminated its collaboration agreements with Ono Pharmaceutical and ImmunoGen.

Risks

• Shattuck Labs is a preclinical-stage company and has incurred significant losses since its inception.
• The company will require additional funding to complete development of its product candidates.
• Shattuck Labs is substantially dependent on the success of its lead product candidate, SL-325.
• The company faces competition from entities that have developed or may develop programs for the diseases addressed by its product candidates.
• Economic downturns, inflation, and public health crises could materially and adversely affect the company's business operations and financial condition.
• The company relies on third parties to supply raw materials and to manufacture its product candidates.
• The company's success depends upon its ability to obtain and maintain patents and other intellectual property rights to protect its technology.

Future Outlook

Shattuck Labs expects to continue incurring significant expenses and operating losses as it advances SL-325 and other product candidates through clinical development. The company believes its current cash resources will fund operations into 2027.

Industry Context

The document highlights the competitive landscape of the pharmaceutical and biotechnology industries, particularly in the development of therapies for immune-mediated diseases. It mentions several large pharmaceutical companies and other clinical-stage therapeutics targeting the TL1A/DR3 axis, indicating a crowded and competitive market.

Comparison to Industry Standards

• The document compares the placebo-adjusted clinical remission rates of TL1A blocking antibodies (tulisokibart, duvakitug, and RO7790121) to those observed with anti-TNF, anti-IL23, and anti-47 blocking antibodies.
• It mentions that the placebo-adjusted clinical remission rates observed to date with these TL1A blocking antibodies could surpass the monotherapy clinical remission rates observed with anti-TNF, anti-IL23 and anti-47 blocking antibodies if confirmed in one or more of the ongoing third-party Phase 3 clinical trials.
• The document also notes that the IBD landscape is projected to increase from a $23 billion market in 2023 to a $34 billion market in 2030, indicating the potential commercial opportunity for therapies targeting the DR3/TL1A signaling pathway.

Stakeholder Impact

• Shareholders: The company's focus on SL-325 and other pipeline programs could lead to increased shareholder value if successful, but the company's financial losses and dependence on future funding pose risks.
• Employees: The restructuring plan and workforce reduction may have a negative impact on employee morale and job security.
• Patients: The development of SL-325 and other therapies could provide new treatment options for patients with IBD and other immune-mediated diseases.
• Suppliers and Creditors: The company's ability to meet its financial obligations to suppliers and creditors depends on its ability to secure additional funding and generate revenue from its product candidates.

Next Steps

• File an Investigational New Drug (IND) application for SL-325 in the third quarter of 2025.
• Complete enrollment in the Phase 1 clinical trial for SL-325 in the second quarter of 2026.
• Nominate a lead bispecific candidate from the preclinical pipeline in 2025.
• Continue advancing TRIM7 inhibitors through preclinical development for oncology.

Key Dates

Keywords

SL-325, DR3, IBD, Shattuck Labs, Antibody, Clinical Trials, Biotechnology, Inflammatory Bowel Disease, TL1A, Oncology